Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti-PD-1 monotherapy.
blocking antibodies nivolumab and pembrolizumab, have significantly improved survival for patients with advanced melanoma (Robert et al, 2011; Ribas et al, 2015) .
The PD-1 receptor is an inhibitory receptor expressed on activated T and B cells. Its primary ligand, PD-L1, is frequently expressed within the tumour microenvironment such as cancer cells and tumour-infiltrating macrophages. The second ligand, PD-L2, is preferentially expressed by antigen presenting cells (Blank et al, 2004; Pardoll, 2012; Sullivan et al, 2013) .
In the initial phase I clinical trial with nivolumab, Brahmer et al (2010) reported dramatic clinical activity with tumour regressions in several tumour types: colon, renal, lung cancers, and melanoma. Pembrolizumab was initially evaluated in a large phase I trial . In a pooled analysis of 411 advanced melanoma patients, the response rate was 34% after a median follow-up of 18 months and was maintained in 81% of those patients with a median overall survival of 25.9 months (Hamid et al, 2013; Deeks, 2016; Ribas et al, 2016) . Results from two other trials, KEYNOTE-002 and KEYNOTE-006, have since been reported (Ribas et al, 2015; Robert et al, 2015b) . Two pembrolizumab dosages (2 or 10 mg kg À 1 every 3 weeks) were compared with investigator's-choice chemotherapy in patients with ipilimumabrefractory advanced melanoma in KEYNOTE-002. Pembrolizumab demonstrated superior progression-free survival compared with chemotherapy (Ribas et al, 2015) . Pembrolizumab (10 mg kg À 1 every 2 or every 3 weeks) was also compared with ipilimumab (3 mg kg À 1 every 3 weeks) in 834 advanced melanoma patients in KEYNOTE-006 and found significantly improved overall survival compared with ipilimumab (Robert et al, 2015b) . Additionally, nivolumab (3 mg kg À 1 every 2 weeks) was compared with dacarbazine (1000 mg kg À 1 every 3 weeks) in a phase 3, doubleblind, randomised control trial in 418 untreated patients and was associated with significant improvement in overall survival and progression-free survival (Robert et al, 2015a) . These trials have established PD-1 antibodies as an important treatment modality for melanoma.
Although PD-1 blockade represents a major step forward, many patients still fail to respond to this drug. The mechanisms underlying this clinical heterogeneity are currently unknown and may be associated with both tumour intrinsic and extrinsic factors Pitt et al, 2016) . Thus the identification of a clinical predictive model for response is critical due to the following reasons: (1) To allow patients who are unlikely to benefit from anti-PD-1 therapy to be spared from unnecessary risk of toxicity and to rationally select a combination that will better fit them (Hiniker et al, 2015) . (2) To spare those who are likely to respond to PD-1 monotherapy from unnecessary toxicities of a combination immunotherapy approach.
Biomarkers associated with both tumour intrinsic and extrinsic factors have been recently investigated, however, none have yet been established to clearly predict response to anti-PD-1 monotherapy . Previous studies that assayed PD-L1 expression on tumour cells using traditional immunohistochemical approaches reported an association between high expression and clinical response to pembrolizumab (Kefford et al, 2014) or nivolumab (Topalian et al, 2012; Weber et al, 2013; Taube et al, 2014) . The tumour immune phenotype has also been investigated, and CD8 þ T cells have been suggested as a potential biomarker in several studies; Tumeh et al (2014) reported that preexisting CD8 þ T cells in the tumour microenvironment were required for tumour regression after treatment with pembrolizumab. Additionally, our group has recently reported relative abundance of 'exhausted' or PD-1/CTLA-4 dual-positive CD8 cells as a biomarker to predict response to anti-PD-1, using a multiparameter flow cytometry on freshly isolated melanoma samples Treatment outcomes. The primary outcome measure was tumour response to treatment, which was evaluated using CT imaging at 12 and 16 weeks after the first infusion, and every 12 weeks thereafter. The Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to define objective clinical responses by a investigatoradjudicated review. Sites of metastases were determined using CT imaging and were not limited to RECIST-defined target lesions. The primary site of melanoma was based on clinical documentation prior to enrollment. Two treatment outcome groups, responders and non-responders, were defined using CT imaging following the treatment. Responders included patients with tumour target lesion that met RECIST v1.1 criteria for complete response (499% reduction in the tumour size) or partial response (X30% radiographic reduction in tumour size). Non-responders included patients with tumour target lesions that met RECIST 1.1 criteria for progression (X20% increase in the target lesion) or stable disease (o30% reduction or o20% increase in tumour target lesions).
Statistical analysis. Patient characteristics are summarised using means and s.d. for continuous variables and percentages for categorical variables. The final data set was divided into two parts: the derivation and the validation cohorts. The derivation cohort was used to develop the clinical prediction scale for tumour response, and the validation cohort was used to assess how well the scale predicted tumour response. LDH was analysed by the means of LDH-ratio (LDH value divided by the institutional upper limit of normal). Abnormal LDH was set at a cutoff of '1' (LDH ratio 41).
Logistic regression was used to assess the possible association between response to anti-PD-1 and the following set of prespecified variables: age, sex, primary site, abnormal LDH, WBC, ECOG performance status, liver metastasis, lung metastasis, brain metastasis, history of ipilimumab treatment, BRAF mutation status, metastatic stage, and history of treatment with targeted therapy.
Variables with significant association on univariate analysis were entered into a stepwise logistic regression model; the P value threshold to enter/leave the model was set to 0.05. A simple and easy clinical tumour response prediction formula, which produces a score for each subject ranging from 0 to 7, was developed using the estimated coefficients of the variables in the final model.
To assess the performance of the score, the formula was used to calculate scores for the validation cohort, and the resulting scores were used to predict tumour response. Discrimination of performance of risk index was assessed using area under the receiver-operating curve (AUC). The Hosmer-Lemeshow goodness-of-fit statistic was used to test the calibration.
RESULTS
Derivation of clinical scale. Demographic and clinical characteristics are summarised in Table 1 . The majority of the derivation cohort patients (n ¼ 228) were aged o65 years (126 patients, 55.3%) and male (148 patients, 64.9%), with M1c metastatic stage (n ¼ 133, 58.3%) and ECOG performance status 0 (157 patients, 68.9%).
Sixty-eight patients had liver metastasis (29.8%), 132 patients had lung metastasis (57.9%) and only 50 patients had brain metastasis (21.9%). Less than 50% of patients were treated previously with targeted therapy (54 patients, 23.7%). However, the majority of patients were treated previously with ipilimumab (147 patients, 64.5%). Of the 228 derivation cohort patients, 44.3% responded to anti-PD-1 therapy (101 of 228) while 55.7% did not respond (127 of 228). Table 2 A formula (clinical prediction scale) based on the estimated coefficients from the logistic model was derived so that a score ranging from 0 to 7 was calculated for each subject. An increase in the score on the scale corresponded to a significantly lower response to anti-PD-1 therapy (Po0.05). The final clinical prediction scale included 5 prognostic factors that were significantly correlated with lower response: female sex (1 point), age o65 years (1 point), previous ipilimumab treatment (2 points), elevated LDH (1 point), and the presence of liver metastasis (2 points). The developed scale had a fair performance in predicting response to anti-PD-1: AUC 0.73 (95% CI 0.67, 0.80) (Figure 2A ).
Validation of clinical prediction scale. Our scoring model was validated in a separate cohort of patients. The validation cohort included 87 patients diagnosed with advanced melanoma at TACRI. Of the 87 validation cohort patients, 63.3% responded to anti-PD-1 therapy (55 of 87), whereas 36.7% did not respond (32 of 87). The scale maintained a discrimination power, AUC 0.70 (95% CI 0.58, 0.81) ( Figure 2B ). Table 4 presents the validation of the clinical prediction scale by response probability. An increase in the score on the scale corresponded to a lower probability of 337 patients with advanced melanoma treated with either pembrolizumab (2 or 10 mg kg response; the estimate probability of response for patients who scored '6' was 29% (95% CI 13, 52) and the estimate probability of response for patients who scored '0' was 87% (95% CI 71, 95). None of the patients in the validation cohort scored '7'.
DISCUSSION
We developed and validated a clinical prediction scale for response to anti-PD-1 monotherapy. The response index had good predictive performance that was maintained in the validation cohort with good calibration. The prediction scale to response to anti-PD-1 was developed using stepwise logistic regression and included five variables that were significantly associated with lower response to anti-PD-1: female sex, age o65 years, history of ipilimumab treatment, elevated LDH, and the presence of liver metastasis. Although anti-PD-1 therapy has transformed the systemic treatment of advanced melanoma, the majority of patients still fail to respond to anti-PD-1 monotherapy; the clinical data indicates that the response rates for patients treated with anti-PD-1 immunotherapy rarely exceed 45% (Brahmer et al, 2010; Hamid et al, 2013; Ribas et al, 2016) . In this study, the response rate of the derivation cohort was about 44.3%, which is consistent with the literature.
As understanding and exploiting this clinical heterogeneity could result in better outcomes, biomarker research remains a very active area of clinical investigation, and characteristics of the tumour microenvironment have been shown to predict response to immunotherapy (Tumeh et al, 2014; Blank et al, 2016; Daud et al, 2016; Pitt et al, 2016) . Assays for PD-L1 upregulation and characterisation of a partially exhausted T-cell phenotype, for example, have been strongly associated with effective response to anti-PD-1 (Herbst et al, 2014; Taube et al, 2014; Tumeh et al, 2014; Daud et al, 2016) .
To date, however, there is less understanding of the impact of host factors on response to PD-1 blockade. A recent study investigating baseline biomarkers predicting outcomes of pembrolizumab-treated melanoma patients reported a better prognosis for patients with high relative eosinophil count, high relative lymphocyte count, low LDH and the absence of metastasis other than soft tissue/lung . Additional characteristics, such as age, diet, germline polymorphisms, pre-existing immunosuppression and chronic infections, and the gut microbiome have been also proposed to influence response to immune checkpoint inhibition (Pitt et al, 2016; Spranger et al, 2016) . The effect of age, in particular, has been an area of debate. An aging, senescent immune system has been long thought to experience many alterations, including an increase in suppressive immune cell populations, such as MDSCs and Treg cells (Pawelec et al, 2010; Goronzy and Weyand, 2013) , and MDSCs have been reported as potential predictors of resistance to ipilimumab therapy (Meyer et al, 2014; Martens et al, 2016) , which would suggest a similar effect in anti-PD-1-treated patients.
Interestingly, a recent meta-analysis (Nishijima et al, 2016 ) comparing efficacy of immune checkpoint inhibition in younger and older patients showed overall survival benefit in both groups, although an exception was seen in a subgroup of older patients in four anti-PD-1 trials who did not demonstrate OS improvement. Although this is different than our findings that younger age is correlated with decreased anti-PD-1 efficacy, it is interesting to note that the age cutoff used for this analysis was X75 years. Although there was no OS benefit observed in patients aged X75 years, a consistent survival benefit was still observed in patients aged 65-75 years. Although this observation was made at the metaanalysis level and across a heterogeneous group of clinical trials and needs to be confirmed with adequate power, this preliminary data seems to suggest that patients over a certain age do just as well as their younger counterparts and, in light of our scoring model correlating greater anti-PD-1 efficacy in patients aged X65 years, potentially may have even better response. This observation is certainly hypothesis generating and needs further prospective validation.
The role of sex in response to immunotherapy is also much debated. Although female sex was found to be a negative prognostic indicator in our model, the mechanisms of this remain poorly defined. Indeed, much of the current literature actually supports a survival benefit for females with advanced melanoma, although of note, much of this data preceded the advent of immune checkpoint inhibition (Manola et al, 2000; Dronca et al, 2013; Nosrati and Wei, 2014) . Though it is speculated that the increased number and/or improved function of tumour-specific T-helper cells in women could underlie this clinical observation, data regarding the role of sex-hormone modulation of PD-1 are currently limited to preclinical models (Polanczyk et al, 2006 (Polanczyk et al, , 2007 . Further work of this nature needs to be carried out to identify and elucidate the nature of sex-dependent differences in immunoregulatory pathways in patients with advanced cancer (Dronca and Dong, 2015) .
Given the relative novelty of this field, the influence of host factors on immunotherapy response requires further research. The factors elucidated in this clinical scale represent one further step in that direction, while also addressing the pressing clinical need for a clinical prediction-scoring model to help guide treatment choice. A model to identify those patients who are likely to respond to anti-PD-1 monotherapy would spare them the additional toxicity of combination CTLA-4/PD-1 blockade; conversely, the ability to identify patients who are unlikely to respond to PD-1 monotherapy would also be helpful in determining the most appropriate treatment option. Those patients, for example, may have improved outcomes with molecularly targeted agents (if their melanomas harbour BRAF V600 mutations) or with a more aggressive immunotherapy regimen (combination ipilimumab/nivolumab) or a clinical trial, rather than with an anti-PD-1 agent alone.
Although our study included a large cohort of patients from four different centres, considering the retrospective nature of this study, a patient selection bias cannot be excluded. Additionally, even though our scoring model had a fair prediction probability for response in the validation cohort, this is based on a relatively small sample of patients, and prospective validation with a larger sample is needed. Additionally, the high response rate in our validation cohort (63.3%) could have affected the ROC reported in our study. Furthermore, the effect of active brain metastasis on patients' response was not studied as the trials included in our study excluded patients with active brain metastasis. Finally, we could not study the effect of pretreatment with ipilimumab in a separate independent model owing to a low number of ipilimumab-naive patients. However, in the four centres included in our study, treatment with pembrolizumab was initiated in a minimum of 6 weeks following the last ipilimumab treatment. To our knowledge, this is the first clinical scoring model developed to predict response to anti-PD-1 monotherapy. This scoring model was developed in a large cohort of patients who were treated with anti-PD-1 monotherapy and validated in a unique set of patients from a separate facility in an effort to strengthen its external validity. Although biomarker development in immunotherapeutics remains an active area of research, most biomarkers to date require accession of tumour tissue and complex laboratory diagnostics to predict response. With this scale, we sought to create a clinical tool that would be readily accessible in a wide range of clinical settings, without the need for additional biopsies or complex computing.
We acknowledge that our scale is only the beginning and additional data regarding host factors, and tumour characteristics from ongoing studies will greatly help in refining and modifying the current effort.
